secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001437749-24-037515
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 2.01, 5.06, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella completes merger with Pieris, raises $78.9M PIPE, ticker changes to PVLA
--------------------------------------------------------------------------------

- Merger closed Dec 13, 2024; Former Palvella survives as wholly-owned subsidiary; name changed to Palvella Therapeutics, Inc.
- PIPE financing raised $78.9M: $60.0M cash + conversion of $18.9M convertible notes; 3.17M shares and 2.47M pre-funded warrants issued.
- Post-merger shares outstanding ~11.2M; Former Palvella securityholders own 81.61% on fully diluted basis; legacy Pieris stockholders own 18.39%.
- CVRs issued to pre-merger Pieris stockholders, entitling them to future payments from certain strategic partner agreements and tax credits.
- New business is clinical-stage rare-disease skin therapeutics; lead program QTORIN rapamycin for vascular malformations; ticker changes to PVLA Dec 16.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000143774924037515/0001437749-24-037515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000143774924037515/pirs20241210_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-037515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer